# AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT02420587** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AMG 208
- **BEHAVIORAL:** Questionnaire

## Key facts

- **NCT ID:** NCT02420587
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2019-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420587, "AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT02420587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*